Tudor Investment Corp ET AL Reduces Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Tudor Investment Corp ET AL cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 45.2% during the 3rd quarter, Holdings Channel reports. The firm owned 98,175 shares of the biotechnology company’s stock after selling 80,909 shares during the period. Tudor Investment Corp ET AL’s holdings in BioCryst Pharmaceuticals were worth $745,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Deerfield Management Company L.P. lifted its holdings in BioCryst Pharmaceuticals by 159.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of BioCryst Pharmaceuticals by 2,103.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after buying an additional 4,084,403 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of BioCryst Pharmaceuticals by 152.3% during the second quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock valued at $21,266,000 after buying an additional 1,432,824 shares during the period. Bank of America Corp DE raised its holdings in shares of BioCryst Pharmaceuticals by 97.9% during the second quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock valued at $25,457,000 after acquiring an additional 1,405,498 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in BioCryst Pharmaceuticals by 1,059.7% in the second quarter. BNP Paribas Financial Markets now owns 1,456,857 shares of the biotechnology company’s stock worth $13,053,000 after acquiring an additional 1,331,230 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the sale, the insider directly owned 400,703 shares of the company’s stock, valued at $3,666,432.45. This represents a 27.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 0.7%

BCRX opened at $9.52 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.31. The stock has a market cap of $2.39 billion, a PE ratio of 7.93 and a beta of 0.74. The business has a 50 day moving average of $7.88 and a 200-day moving average of $7.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.05. The company had revenue of $163.28 million for the quarter, compared to analysts’ expectations of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The firm’s revenue for the quarter was up 209.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.13) earnings per share. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Weiss Ratings upgraded shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Royal Bank Of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Evercore began coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price on the stock. Finally, HC Wainwright boosted their price target on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.64.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.